The U.S. Food and Drug Administration approved a high dose regimen of Biogen Inc.'s (NASDAQ: BIIB) SPINRAZA (nusinersen) for treating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE